Take Solutions
- Market cap
- ₹ 160 Cr.
- P/E
- 27.4x
- P/B
- 5.49x
- 52-week range
- 9.88 – 50.14
- ROE
- 17%
- ROCE
- 19%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- NSE, BSE
About
Take Solutions Limited is an India-based contract research organization (CRO), which is engaged in supporting pharma, biotech and devices companies. The Company offers clients a combination of full-service clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance/safety services. Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry network forums. Its digital healthcare services include medical decision-making (artificial intelligence and machine learning), and cloud adoption & mobility. Its global roster of clients includes large and small biopharmaceutical and device companies, United States federal agencies like Centers for Disease Control and Prevention (CDC) and the United States Department of Defense (DoD), as well as generics manufacturers. The Company's subsidiary is Ecron Acunova Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Take Solutions against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)27.4 against a typical 34.2: cheaper than most peers (1st = cheapest).4th of 11
- Share price, 3 months−52% against a typical −13%.11th of 11
- Size₹ 159.7 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).9th of 11
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 20 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 14 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 11 Feb 2026 | Other business matters | Board Meeting Intimation for Board Meeting To Be Held On Wednesday 11Th February 2026 |
| 27 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 7 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54 | 30 |
| Expenses | 2 | 2 | 16 | 2 | 1 | 3 | 1 | 0 | 0 | 0 | 55 | 31 |
| Operating Profit | −1 | −2 | −16 | −2 | −1 | −3 | −1 | −0 | −0 | −0 | −1 | −0 |
| OPM % | −2,900% | — | — | — | — | — | — | — | — | — | −1.5% | −0.9% |
| Other Income | 0 | 4 | −94 | −1 | −0 | 51 | −3 | −0 | 7 | 1 | 5 | 1 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −2 | 1 | −110 | −4 | −2 | 48 | −5 | −1 | 6 | 1 | 4 | 1 |
| Tax % | −18.4% | 248.6% | 0.6% | 1.6% | −3.7% | 0% | 0% | 0% | 2.5% | 0% | 0% | 0% |
| Net Profit | −2 | −2 | −111 | −4 | −2 | 48 | −5 | −1 | 6 | 1 | 4 | 1 |
| EPS in Rs | −0.1 | −0.14 | −7.48 | −0.25 | −0.11 | 3.22 | −0.33 | −0.06 | 0.43 | 0.08 | 0.29 | 0.07 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −26%
- 5 Years
- −41%
- 3 Years
- −34%
- TTM
- —
- 10 Years
- −27%
- 5 Years
- 15%
- 3 Years
- 27%
- TTM
- 80%
- 10 Years
- −19%
- 5 Years
- −16%
- 3 Years
- 4%
- TTM
- —
- 10 Years
- −10%
- 5 Years
- −104%
- 3 Years
- −47%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Take Solutions | ₹ 10.62 | ₹ 160 Cr. | 27.4x | 5.5x | 17% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.6x | 5.6x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 86.8x | 13.6x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.6x | 19.7x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 22.1x | 4.4x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.4x | 3.4x | 0% | 0% |
Management
- Vandana Gupta
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.